View article

Aim/Background: Cisplatin has been a backbone for Germ Cell Tumors (GCT) since its introduction in 1970. Cure has been achieved with use of platinum agents even in metastatic settings. More emphasis is now on reducing therapy related complications. A lot of data suggest that the use of Cisplatin in GCTs is associated with increased risk of thromboembolic events. Although this has merely been an association without definite evidence but it has significant morbidity & mortality. We conducted a retrospective analysis to see frequency of these events in our patients with GCTs on Platinum based chemotherapy.

Methods: Retrospectivly, 129 male GCT patients registered between Jan 2011 to Apr 2014 were evaluated for thromboembolic complications. Events were considered to be associated with Platinum if these occurred during the chemotherapy or within 8 weeks of treatment completion. Data were collected on …